Imatinib mesylate use in refractory eosinophilic granulomatosis with polyangiitis: a literature review and a case report

The target landscape of clinical kinase drugs

(2017) Susan Klaeger et al.   SCIENCE

Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome

(2016) P. Khoury et al.   ALLERGY

Imatinib mesylate for unmutated hypereosinophilic syndromes: Does it work?

(2016) Grzegorz Helbig   European Journal of Internal Medicine

Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen Patients

(2016) Marie Jachiet et al.   Arthritis & Rheumatology

Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?

(2015) Iwona Gagalo et al.   Current Neuropharmacology

Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management

(2015) Matthieu Groh et al.   European Journal of Internal Medicine

Is there a role for imatinib mesylate in the treatment of eosinophilic granulomatosis with polyangiitis?

(2015) Gian Luca Erre et al.   JOINT BONE SPINE

Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study

(2015) Aikaterini Detoraki et al.   JOURNAL OF ASTHMA

First report ofFIP1L1-PDGFRα-positive eosinophilic granulomatosis with polyangiitis : Fig. 1

(2015) Giacomo Emmi et al.   RHEUMATOLOGY

Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg–Strauss)

(2014) A J Mohammad et al.   ANNALS OF THE RHEUMATIC DISEASES

Tracking anti-fibrotic pathways of nilotinib and imatinib in experimentally induced liver fibrosis: An insight

(2014) Gamal E Shiha et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Effects of imatinib mesylate on pulmonary allergic vasculitis in a murine model

(2013) Naomi Suzuki et al.   International Journal of Rheumatic Diseases

Imatinib: Novel Treatment of Immune-Mediated Kidney Injury

(2013) E. Wallace et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Efficacy of imatinib mesylate in a case of Churg-Strauss syndrome: evidence for the pathogenic role of a tyrosine kinase?

(2013) L. Josselin-Mahr et al.   RHEUMATOLOGY

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort

(2012) Cloé Comarmond et al.   ARTHRITIS AND RHEUMATISM

Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial

(2012) S. Prey et al.   BRITISH JOURNAL OF DERMATOLOGY

Low-dose imatinib in the treatment of severe systemic sclerosis: a case series of six Chinese patients and literature review

(2012) Li Guo et al.   CLINICAL RHEUMATOLOGY

Inhibition of radiation-induced skin fibrosis with imatinib

(2012) Jason A. Horton et al.   INTERNATIONAL JOURNAL OF RADIATION BIOLOGY

Therapeutic Inhibition of Tyrosine Kinases in Systemic Sclerosis: A Review of Published Experience on the First 108 Patients Treated with Imatinib

(2012) Vasiliki-Kalliopi Bournia et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Imatinib Therapy for Non–Infection-Related Type II Cryoglobulinemia With Membranoproliferative Glomerulonephritis

(2011) Eric Wallace et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Imatinib-Sensitive Tyrosine Kinases Regulate Mycobacterial Pathogenesis and Represent Therapeutic Targets against Tuberculosis

(2011) Ruth J. Napier et al.   Cell Host & Microbe

Imatinib Mesylate Improves Liver Regeneration and Attenuates Liver Fibrogenesis in CCL4-Treated Mice

(2011) Wen-Ling Kuo et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Antifibrotic effect after low-dose imatinib mesylate treatment in patients with nephrogenic systemic fibrosis: an open-label non-randomized, uncontrolled clinical trial

(2011) T.R. Elmholdt et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Early short-term imatinib treatment is sufficient to prevent the development of chronic allograft nephropathy

(2011) J. Savikko et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome

(2010) B. Terrier et al.   BLOOD

Imatinib mesylate, a new kid on the block for the treatment of anti-neutrophil cytoplasmic autoantibodies-associated vasculitis?

(2010) A.-I. Kälsch et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Imatinib Treatment for Idiopathic Pulmonary Fibrosis

(2009) Craig E. Daniels et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis

(2009) Alfiya Akhmetshina et al.   ARTHRITIS AND RHEUMATISM

Imatinib mesylate inhibited rat adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference with the Akt signaling pathway

(2009) Fumitaka Terabe et al.   Modern Rheumatology

Portopulmonary Hypertension: Imatinib as a Novel Treatment and the Emory Experience With this Condition

(2009) E.B. Tapper et al.   TRANSPLANTATION PROCEEDINGS

The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)

(2009) Jonathan A Winger et al.   BMC STRUCTURAL BIOLOGY

Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome - a phase-II study

(2008) Georgia Metzgeroth et al.   BRITISH JOURNAL OF HAEMATOLOGY

Imatinib Suppresses Cryoglobulinemia and Secondary Membranoproliferative Glomerulonephritis

(2008) M. Iyoda et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY